Zhen Jun, Chen Tao, Kong Mei, Li Zhendong, Kou Li, Liu Hanwei, Zhang Lei
The Fifth Affiliated Hospital of Zhongshan University, Zhuhai 519000, China.
Zhongguo Zhong Yao Za Zhi. 2011 Sep;36(18):2584-7.
To observe the clinical effect and the influences of Shuxuetong injection on serum neuron-specific enolase (NSE) level, the neurological deficit and activities of daily living in patients with acute cerebral infarction.
The 80 patients with acute cerebral infarction were randomly divided into Shuxuetong treatment group (40 cases) and routine control group (40 cases), both received routine treatment, while Shuxuetong injection was given additionally to treatment group. The serum NSE level, the National Insitute of Health Stroke Scale (NIHSS) scores and the clinical effect were observed pre-and post-treatment. The Barthel Index (BI) was evaluated after one month.
The serum NSE level and NIHSS scores in two groups of post-treatment decreased obviously than those of pre-treatment, and after treatment in Shuxuetong treatment group the serum NSE level and NIHSS scores were significantly lower than those in control group, the differences were significant (P<0.05). Effective rate of Shuxuetong treatment group was 87.5%, and control group was 65%, the difference of the clinical effect between the two groups was significance (P<0.05). After one month BI of post-treatment in two groups improved than those of pre-treatment, and Shuxuetong treatment group was significantly better compared with control group (P<0.05).
Shuxuetong injection has the remarkable neuronal protective effect, can decrease the serum level of NSE after acute cerebral infarction, promote recovery of nerve function, reduce disability rate, and improve quality of life and prognosis of patients with acute cerebral infarction.
观察舒血宁注射液对急性脑梗死患者的临床疗效以及对血清神经元特异性烯醇化酶(NSE)水平、神经功能缺损和日常生活活动能力的影响。
将80例急性脑梗死患者随机分为舒血宁治疗组(40例)和常规对照组(40例),两组均接受常规治疗,治疗组另加用舒血宁注射液。观察治疗前后血清NSE水平、美国国立卫生研究院卒中量表(NIHSS)评分及临床疗效。1个月后评估巴氏指数(BI)。
两组治疗后血清NSE水平和NIHSS评分均较治疗前明显降低,且舒血宁治疗组治疗后血清NSE水平和NIHSS评分显著低于对照组,差异有统计学意义(P<0.05)。舒血宁治疗组有效率为87.5%,对照组为65%,两组临床疗效差异有统计学意义(P<0.05)。两组治疗后1个月的BI均较治疗前有所改善,且舒血宁治疗组明显优于对照组(P<0.05)。
舒血宁注射液具有显著的神经保护作用,能降低急性脑梗死患者血清NSE水平,促进神经功能恢复,降低致残率,提高急性脑梗死患者的生活质量和预后。